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Abstract: In the last decade there has been tremendous effort in offering better therapeutic management
strategies to patients with hematologic malignancies. These efforts have ranged from biological to
clinical approaches and resulted in the rapid development of new approaches. The main “problem”
that comes with the high influx of newly approved drugs, which not only influences hematologists
that frequently work with these drugs but also affects other healthcare professionals that work
with hematologists in patient management, including intensive care unit (ICU) physicians, is they
have to keep up within their specialty and, in addition, with the side-effects that can occur when
encountering hematology-specific therapies. Nonetheless, there are few people that have an in-depth
understanding of a specialty outside theirs. Thus, this manuscript offers an overview of the most
common side-effects caused by therapies used in hematology nowadays, or that are currently being
investigated in clinical trials, with the purpose to serve as an aid to other specialties. Nevertheless,
because of the high amount of information on this subject, each chapter will offer an overview of the
side-effects of a drug class with each reference of the section being intended as further reading.
Keywords: novel therapies; life-threatening side-effects; hematological malignancies
1. Introduction
The last decade has brought forward tremendous effort in offering better therapeutic management
strategies to patients with hematologic malignancies. These efforts have taken either translational or
clinical approaches and resulted in the rapid development of new approaches that are more tailored
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to the disease and the patient [1]. These range from the development of chimeric antigen receptor
T-cells (CAR-T cells) to small inhibitory molecules and different varieties of antibodies. Nevertheless,
this rapid development of a wide variety of targets is accompanied by a myriad of side-effects, most of
which are interdisciplinary and involve clinical scenarios that are challenging both for hematologists
and intensive care unit (ICU) physicians. In treating a patient diagnosed with a hematological
malignancy, hematologists and oncologists collaborate with other medical specialties to provide a
better outcome, and this often includes the departments of cardiology, pneumology or nephrology.
Thus, all clinicians have to be up-to-date with the latest progress in immunotherapy and stem cell
transplantation. To meet this endeavor, this manuscript offers an overview of the side-effects of novel
therapies for all malignancies in order to improve the management of patients under these treatments.
2. Specific Targets in Hematology
Figure 1 shows the typical targets in the main hematological malignancies. Based on this
structure, we further present each individual drug for each of these targets and highlight the target-
specific side-effects.
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Historically, one of the most important targets in malignant hematology is the fusion protein
BCR-ABL in chronic myeloid leukemia (CML). The discovery that BCR-ABL can be efficiently targeted
has greatly improved the survival of CML patients [2]. BCR-ABL inhibitors are classified into three
generations, and each of the individual drugs present specific side-effects. Imatinib is the first BCR-ABL
inhibitor for CML, and it is the first generation of this class of drugs to which other members of the
class are frequently compared. Imatinib has a safe side-effect profile, with most patients tolerating
it well. Some common side-effects that can appear in this case are represented by nausea, vomiting,
muscle and joint pain, headache and diarrhea [3]. The second generation of BCR-ABL inhibitors
is represented by nilotinib, dasatinib and bosutinib. It should be mentioned that there is a certain
tendency in Europe to use nilotinib and in the United States to use dasatinib. Each of these three has a
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characteristic side-effect that is worse and more frequent when compared to imatinib. Nilotinib is more
frequently associated with cardiovascular events, whereas dasatinib is associated with pleural effusion
and bosutinib with gastrointestinal conditions, especially diarrhea. The third generation is represented
by ponatinib, which is also the most potent and can be efficient even for CML patients where resistance
develops to first- and second-generation drugs. Nonetheless, the most marked side-effect of this drug is
represented by cardiovascular events that are worse and more frequent than in the case of nilotinib [4].
Generally, drugs that match the patient’s comorbidities with their side-effects should be avoided.
Quite frequently, imatinib will be the first choice when treating CML and will be changed to a
second-generation BCR-ABL inhibitor if the disease progresses or if the patient presents intolerance
to imatinib [4].
One of the targets for a varied repertoire of drugs, which is expressed on the surface of multiple
hematological malignancies, is CD20. For anti-CD20 targets, most side-effects are target-related,
as anti-CD20 therapy determines B-cell depletion, with most of these patients requiring immunoglobulin
substitution [5]. Nonetheless, most cases receiving substitution do not report an increase in infections
with encapsulated bacteria, showing the efficacy of this countermeasure. Similarly, some therapies target
CD19, which presents a similar mechanism of action as in the case of anti-CD20 therapy. These drugs
also target B-cells and require immunoglobulin substitution [6]. Interestingly, when targeting the B-cell
maturation antigen (BCMA), no important reduction in immunoglobulins is reported when compared
to the case of anti-CD19 or anti-CD20 therapies, even though this antigen is highly expressed on plasma
cells. The main side-effects of anti-BCMA therapy are represented by reactions to the drug itself,
most commonly infusion-related reactions or allergic reactions, in the case of antibodies, and cytokine
release syndrome (CRS) in the case of anti-BCMA CAR-T cells [7].
Another important target for plasma cells is CD38. Targeting CD38 in multiple myeloma generally
has mild side-effects, and the infusion-related reaction is the most prominent. Still, patients receiving
the anti-CD38 drug daratumumab require a special transfusion, as further described [8]. Brentuximab
vedotin, an anti-CD30 therapy, is an excellent therapeutic strategy for classic Hodgkin and peripheral
T-cell lymphomas, and it is used as a single-agent monotherapy that bridges the transplant for T-cell
lymphomas or is used in combination with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)
chemotherapy for stage IV Hodgkin lymphomas [9]. Nonetheless, in addition to the side-effects
associated with the monoclonal antibody-based structure of brentuximab vedotin, CD30 is a marker of
activated T-cells, thus potentially leading to an impairment of these cells. Peripheral neuropathy is a
side-effect that is not life-threatening, but it may lead to the interruption of the treatment or may alter
the patient’s quality of life [10].
One of the targets that significantly impacted treatment of hematological malignancies is BCL2
since its discovery by the team of Croce et al. [11–14]. Currently, the most used drug that targets BCL2
is venetoclax. Currently, this drug impacts a variety of hematological malignancies, most notably
chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [15,16]. The main side-effect
arises from the anti-apoptotic role of BCL2. Because of this, venetoclax is linked to a high tumor lysis
syndrome when used without caution. Nonetheless, this side-effect can be avoided in most cases
through correct dose escalation, prior cytoreduction and renal protection [17].
The checkpoint blockade in cancer was awarded the 2018 Nobel prize in Medicine or
Physiology [18]. It acts by releasing some of the regulatory effects that occur either between the T-cell
and the antigen-presenting cell (APC) or between the T-cell and the malignant cell. Because T-cells
are likely to recognize a more altered antigen repertoire as non-self, checkpoint blockers have a more
significant effect in malignancies with a higher degree of genomic instability. Because of this, nivolumab
and pembrolizumab were approved for use in any malignancy with genomic instability [19]. The main
side-effect of this class of molecules is caused by their T-cell activation mechanism. Still, although it
enhances the action of T-cells against malignant cells, it also increases the probability for T-cells to
recognize self-structures as non-self, leading to autoimmune conditions and associated side-effects [20].
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Immunomodulators, represented by thalidomide, lenalidomide and pomalidomide, act by altering
the targets in the proteasomal degradation pathway, leading to an increased degradation of Ikaros
family zinc family protein 1 (IKZF1) and IKZF3, which in turn reduces myelocytomatosis (MYC)
transcription. Moreover, this class of molecules inhibits the overall proteasomal degradation pathway,
leading to protein accumulation and thus being important for diseases which produce an increased
number of proteins, as in the case of multiple myeloma [21,22]. Apart from the teratogenic effects that
thalidomide is known for, the main side-effects that occur in patients treated with these compounds are
pancytopenia and neuropathic pain. However, besides these two side-effects, the drugs are generally
well tolerated [23,24].
Fms-like tyrosine kinase (FLT3) is an important target especially for FLT3-internal tandem
duplication (ITD) AML, as this alteration is associated with a bad prognosis [25]. The first generation
of FLT3 inhibitors is most frequently represented by midostaurin and the second by gilteritinib and
quizartinib. The side-effect profile of this class is generally well tolerated with increased probability of
developing cytopenias when combined with venetoclax [25–27].
BTK inhibitors are very efficient for the treatment of CLL and have few side-effects, the downside
being a life-long therapy. The side-effect profile is generally well tolerated, so extended use of these
drugs does not lead to significant discomfort for most patients. Nonetheless, ibrutinib, the most
commonly used BTK inhibitor, causes blood thinning and arrhythmias and must be stopped 3 days
before and after a minor surgical intervention, as well as 7 days before and after a major surgical
intervention. Considering that CLL develops over a long period of time, these stops are generally not
of concern [28].
PI3K inhibitors have been included in several clinical trials for lymphoid diseases. Nonetheless,
an important percentage of them were not validated clinically because of the high degree of side-effects
that can occur. The most frequently used compound in this case is idelalisib, which induces severe
diarrhea in many patients. Because of this toxicity, clinical trials for this drug were generally conducted
as monotherapy, as when used in combined therapy they revealed an unacceptable side-effect profile.
Nonetheless, these drugs have been shown to be very active in lymphoid diseases, thus having potential
clinical use if the side-effect profile can be better managed [29]. An important drug that revolutionized
symptom management in primary myelofibrosis is ruxolitinib [30–32]. This drug inhibits both JAK1
and JAK2, thus reducing proinflammatory cytokine levels and, because of this, the size of the spleen
and severity constitutional symptoms. The side-effects that occur in this case are related to the role of
JAK2 as an important transducer in myeloid differentiation and of JAK1 in other cytokine signaling
pathways [33–35]. The first is responsible for inducing pancytopenia to the point that ruxolitinib has to
be reduced or discontinued, and the latter transducer could potentially be responsible for the extreme
weight gain that these patients observe under treatment [36,37].
3. CAR-T Cells and Bispecific Antibodies
A novel category of therapies that must be considered is represented by CAR-T cells. These are
T-cells that are engineered to present a receptor for a specific antigen that, when encountering
the antigen, activate the engineered T-cell. A common effect among this class of therapeutics is
cytokine release syndrome (CRS) that occurs between 60% and 80% of treated patients [38–41]. CRS is
characterized by a massive release of inflammatory cytokines and subsequent multiorgan dysfunction.
Additionally, because of these cytokines, neurological and pulmonary symptoms can occur separately
from CRS. In addition to these class effects, side-effects can also be in accordance to the target of the
CAR-T cell, most notably anti-CD19, also requiring intravenous immunoglobulins [42].
A similar class of therapeutics considering the mechanism of action is represented by bispecific
antibodies. In these cases, one arm of these molecules binds CD3 on T-cells and the other arm binds to
the target antigen, generally represented by CD19 on the malignant clone. Of note, these also present
CRS, but in a smaller proportion compared to CAR-T cells [43].
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To offer an overview of the side-effects of the therapies that are frequently used, we classified
them according to the FDA approval status and on the systems affected (Figures 2–8), and we offer a
summary of their molecular mechanisms that might explain the observed side-effects (Table 1).
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Table 1. Molecular/biological mechanisms behind the observed side-effects of the most common therapeutic strategies applied in hematological malignancies.





Chronic myeloid leukemia, acute
lymphocytic leukemia
â non-specific targeting of other kinases
â increase in endoplasmic reticulum
stress response
â Jun N-terminal kinases non-specific
inhibition, leading to
mitochondrial disfunction
â lowering the available levels of ATP
â targeting of c-Kit leading to
skin hypopigmentation
[44]
anti-CD20 targets B cell (malignant, as wellas normal B cells)
B-cell non-Hodgkin’s lymphoma, B-cell
leukemias
â decrease in total B cell count
â depletion of normal B cells







Primary cutaneous anaplastic large-cell




â CD30 has a very low expression in normal
tissue in comparison with lymphoma cells
â expressed only in the rim of the follicular
centers, proliferating germinal centers, and
thymic medulla
â expressed by activated CD8+/CD4+ T cells







Chronic lymphocytic leukemia (CLL)
and acute myeloid leukemia (AML)
â BCL-2 is a major anti-apoptotic factor in the
mitochondria that suppresses Bax and Bak
molecules and causes the release of
cytochrome C
â in the endoplasmic reticulum, BCL-2
depletes the levels of Ca2+
â BCL-2 disrupts Ca delivery between the
endoplasmic reticulum and mitochondria
â after BCL-2 inhibition, cells undergo
apoptosis very fast, the tumor cells die more
rapidly than the ability of local macrophage
to engulf the cell debris (tumor
lysis syndrome)
â tumor debris causes mineral imbalance in
the blood circulation
[16,17,47]
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T-cells and APCs, or
T-cells and malignant
cells
malignancies with high genomic
instability
â physiological immunosuppression is
stopped throughout the whole body







plasma cells Multiple myeloma
â binds to cereblon, a E3 ubiquitin ligase, that,
together with DNA binding protein 1
(DDB1), Cullin-4A (CUL4A) and regulator of
cullins 1 (ROC1), form the ubiquitin complex
that ubiquitinates several proteins
â IKZF1 and IKZF3 transcription factors,
involved in B and T cell development
are degraded
â B and T cell development is impaired
[50,51]
anti-B-cell maturation
antigen therapy plasma cells Multiple myeloma
â specific for mature B cells, not found in
hematopoietic stem cells
â essential for the survival of plasma cells, but
not for the overall survival of B-cells
[7,52,53]
PI3K inhibitors B cells Lymphoid diseases (especially of B-cellorigin)
â T regs are no longer capable of preventing
auto-reactivity of the effector T-cells
(auto-immune effects)
â angiotensin II cannot function without PI3K
activation (cardiovascular events)
â PI3K inhibition slows calcium intake in








Myelofibrosis, diffuse large B-cell
lymphoma, and peripheral T-cell
lymphoma.
â JAK2 is involved in myeloid maturation, its
down-regulation causes pancytopenia
â JAK1 is involved in production of
pro-inflammatory cytokines, its decrease,
increases the susceptibility to infections
[56–58]
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Table 1. Cont.
Therapeutic Strategy Type of Targeted Cell Type of Hematological Malignancy Mechanism behind Observed Side-Effect Ref.
CAR T cells depending on theengineered target
Wide applications in hematological
malignancies, depending on the
engineered target
â CAR T cells are engineered to be activated
and continuously proliferate when
encountering neoantigens
â CAR T cells form a positive feedback loop:
the more tumor cells they encounter, the
more CAR T cells will be activated
and proliferate
â CAR T cells cause rapid increase in
pro-inflammatory cytokines
[39–42,53]
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4. Conclusions
In the current concise review, we offered an overview of the most common therapies that are used in
hematology with the main interest that other specialties would find this of use when collaborating with a
hematologist. Nonetheless, this should only serve as a primer for understanding the hematologic patient
and should not substitute discussions with a hematologist or further consulting the specific literature.
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